Drugs / GC1119
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01653444 | Nov 2012 → May 2014 | Fabry disease | Green Cross Corporation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC1119 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01653444 ↗ |
| Known as | recombinant human α-galactosidase A | “GC1119 (recombinant human α-galactosidase A)” NCT01653444 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human α-galactosidase A” NCT01653444 ↗ |
| Route | Intravenous | “biweekly, IV infusion” NCT01653444 ↗ |